An analyst from BTIG recently raised the price target for Natera (NASDAQ: NTRA) to $270.00. With the stock's price at $234.76, this new target represents a potential increase of approximately 15.01%. Natera is a global company that operates in the precision medicine field, specializing in cell-free DNA testing technology.
This optimistic view is supported by key company developments. As highlighted by Business Wire, the National Comprehensive Cancer Network® (NCCN®) has updated its guidelines for bladder cancer. The update now recommends using Natera's Signatera™ technology for molecular residual disease (MRD) testing in certain patients, making it part of the standard treatment process.
Natera is also demonstrating its leadership in organ health. The company is scheduled to give 21 presentations at the American Transplant Congress. These presentations focus on the utility of its Prospera test, which is used for risk assessment and monitoring of kidney, heart, and lung transplants.
Specific data from the PEDAL study shows the Prospera test's value. Even when biopsies were negative, elevated levels detected by the test predicted future problems. In these cases, over 18% of patients with positive Prospera results went on to have significantly higher rates of adverse events, including graft loss.
Reflecting these positive events, shares of Natera are trading at $234.76, an increase of 2.60% for the day. The stock has a 52-week range between $131.81 and $256.36. The company's current market capitalization is approximately $33.62 billion, with a daily trading volume of 1.51 million shares.
